Novartis Gets OK On $126M Deal To End Drug Delay Claims
By Nadia Dreid ( January 9, 2023, 8:20 PM EST) -- Novartis will pay $126 million to end claims brought by a group of direct purchasers accusing the pharmaceutical giant of hatching an illegal deal with Par Pharmaceuticals to delay the release of a generic version of the blood pressure drug Exforge....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.